Barclays raised the firm’s price target on Vertex Pharmaceuticals (VRTX) to $467 from $435 and keeps an Equal Weight rating on the shares. The ...

The cystic fibrosis treatment leader exceeded revenue expectations, but missed slightly on earnings per share.

Barclays analyst Gena Wang maintained a Hold rating on Vertex Pharmaceuticals (VRTX – Research Report) today and set a price target of $467.00.

Vertex (VRTX) stock was trading largely flat post-market after the company released its Q4 earnings report and issued 2025 ...

Vertex Pharmaceuticals (VRTX) reports Q4 earnings today. Investors are eager for updates on new drug launches and growth ...

Vertex Pharmaceuticals Inc. will soon lose a member of its leadership team that helped the company achieve major revenue growth over the past decade.

Vertex Pharmaceuticals ( VRTX) reported fourth-quarter revenue and offered an outlook for 2025 that topped analysts’ expectations. The company said it anticipates 2025 revenue of $11.75 billion to $12 ...

Filming is underway on My Secret Santa, a brand-new live-action romantic comedy that will likely be part of Netflix’s 2025 Christmas lineup. To celebrate, Netflix has announced four new cast members.